Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Receivables - Net: 2011-2024

Historic Receivables - Net for Amicus Therapeutics (FOLD) over the last 12 years, with Dec 2024 value amounting to $101.1 million.

  • Amicus Therapeutics' Receivables - Net rose 16.07% to $113.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.8 million, marking a year-over-year increase of 16.07%. This contributed to the annual value of $101.1 million for FY2024, which is 15.37% up from last year.
  • Latest data reveals that Amicus Therapeutics reported Receivables - Net of $101.1 million as of FY2024, which was up 15.37% from $87.6 million recorded in FY2023.
  • In the past 5 years, Amicus Therapeutics' Receivables - Net registered a high of $101.1 million during FY2024, and its lowest value of $46.9 million during FY2020.
  • For the 3-year period, Amicus Therapeutics' Receivables - Net averaged around $85.0 million, with its median value being $87.6 million (2023).
  • Data for Amicus Therapeutics' Receivables - Net shows a peak YoY soared of 40.98% (in 2020) over the last 5 years.
  • Amicus Therapeutics' Receivables - Net (Yearly) stood at $46.9 million in 2020, then increased by 12.25% to $52.7 million in 2021, then grew by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then rose by 15.37% to $101.1 million in 2024.